In summary, our findings confirmed that α-KG enhanced the immunotherapeutic efficacy of anti-PD1 through the TET2/3-STAT1/3-CD274 pathway and that supplementation with α-KG plus treatment with anti-PD1 might be a novel strategy for melanoma treatment. This evidence concerns the gene CD274 and melanoma.